Skip to content

Effect of sufentanil on the effective dose of ciprofol during anesthesia induction in elderly patients

Effect of sufentanil on the effective dose of ciprofol during anesthesia induction in elderly patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090926
Enrollment
Unknown
Registered
2024-10-16
Start date
2024-10-18
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General anesthesia induction in elderly patients

Interventions

Sufentanil + ciprofol group:Sufentanil was administered at 0.1 µg/kg, followed five minutes later by the initial dose of ciprofol (0.3 mg/kg). The subsequent dose of the latter patient was increased
ciprofol group:5 ml of normal saline was given first, and the initial dose of ciprofol (0.3 mg/kg) was given five minutes later. The subsequent dose of the latter patient was increased or decreased b

Sponsors

Hangzhou Linping District first People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: ? 65-85 years old; ? Surgery under general anesthesia is required; ?ASA (American Society of Anesthesiologists) Levels I-III; ? Body mass index (BMI) between 18-25 kg/m^2;

Exclusion criteria

Exclusion criteria: ? Allergic to cyclopofol or contraindicated to the use of cyclopofol (soybean allergy) Preoperative disturbance of consciousness or chronic pain Long-term use of analgesics, psychotropic drugs (including opioids, NSAIDs, sedatives, antidepressants) ? The patient is expected to have a difficult airway or a history of abnormal anesthesia (4) Patients with tumors and serious cardiovascular and cerebrovascular diseases 5. Use of sedatives, antiemetic, antipruritic drugs 24 hours before surgery, or use of monoamine oxidase inhibitors or antidepressants within 15 days ? Researchers who do not agree to participate in or are participating in other drug trials

Design outcomes

Primary

MeasureTime frame
Eeg bispectral index;

Secondary

MeasureTime frame
Blood Pressure;HeartRate;Saturation of Pulse Oxygenation;Injection pain;hypotension;bradycardia;myofibrillation;Postoperative nausea and vomiting;Respiratory depression;Low oxygen sats;

Countries

china

Contacts

Public ContactQing Han

Hangzhou Linping District first People's Hospital

hanqing1029@126.com+86 159 9010 7935

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026